Female Pelvic Implants Market to exhibit growth at a CAGR of 2.8% between 2021 and 2031
According to a recent report by Future Market Insights (FMI), rising prevalence of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) is expected to boost the growth opportunities for female pelvic implants market. The market is set to reach a valuation of US$ 245 Mn in 2021, rising at a CAGR of 2.8% through the end of 2031.
Increasing incidence of vaginal disorders among aged women coupled with the non-availability of other treatment options for SUI and POP will continue increasing the demand in the female pelvic implants market. According to the U.S. FDA, the number of women who have POP is estimated to surge by 46%, to 4.9 million, by 2050.
According to the American Urological Association (AUA/SUFU), the incidence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The incidence of stress urinary incontinence is high in women with poor or weakened pelvic supports. This disease affects the lives of women to a great extent and is widespread in the older population.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3422
However, the low rate of efficacy after pelvic implantation and the problems of pelvic organ prolapse are hampering the growth of the female pelvic implants market. COVID-19 is anticipated to have a moderately negative impact on the female pelvic implants market due to implementation of lockdown. Supplies and demand were jolted by the massive spread of the infection, which staggered the growth of the female pelvic implants market.
Key Takeaways from Female Pelvic Implants Market Study
- Vaginal sling/tapes demand is anticipated to gain maximum revenue share of more than 68%, rising at an expected CAGR of 2.5% owing to the high demand to treat stress urinary incontinence.
- Hospitals followed by ambulatory surgical centers are leading users of female pelvic implants growing owing to the rising number of POP and SUI patients.
- The U.S. accounts for more than 83% of the North America market, driven by the high incidence of pelvic organ prolapse.
- The U.K.is a leading market in Europe. It is expected to account for nearly 13% of demand registered in Europe by 2031. Implementation of government funded awareness programs will remain a chief growth driver.
- Over 30% of the South Asia market is held by India. Growth in the country is propelled by significant investments in the expansion of healthcare sector.
“Rising prevalence of stress urinary incontinence (SUI) and pelvic organ prolapse (POP) amidst a rapidly expanding geriatric patient base and increasing investments into creating awareness programs will drive the female pelvic implants market through 2031,” says the FMI Analyst.
Post-Marketing Surveillance of Approved Devices Influencing Female Pelvic Implants DemandAn increasing number of manufacturers are continuing to sell their products in the global market despite restrictions by law. After the FDA reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies to assess impacts of organ damage and other complications of mesh implants.
After assessing the risks, manufacturers can reintroduce their devices and can get pre-market approval from the FDA. This allows manufacturers to re-launch the mesh implants, which is expected to come into the market by 2022.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3422
Who is Winning?Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to strengthen their product portfolios in the female pelvic implants market.
For instance, Coloplast acquired Nine Continents Medical, Inc. in November 2020 and aimed to expand its medical device product portfolio.
The FDA, in 2019 completed its broad evaluation of data associated with the resin used in the production of Boston Scientific’s vaginal mesh through which, the US federal law limits these devices to sale by order of a surgeon.
Want More Insights?Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Female Pelvic Implants Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Female Pelvic Implants Market on basis of product type [Vaginal Mesh Implants, Vaginal Sling/Tape and Vaginal Graft Implants], Indication [Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)]. Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.
Market TaxonomyProduct Type
- Vaginal Mesh Implants
- Vaginal Sling
- Vaginal Graft Implants
- Pelvic Organ Prolapse
- Stress Urinary Incontinence
- Ambulatory Surgical Centres
- Speciality Clinics
- North America
- Latin America
- Western Europe
- Eastern Europe
For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3422